We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
S&P Futures
5,180.75 +13.25 (+0.26%) Dow Futures
38,321.00 +83.00 (+0.22%) Nasdaq Futures
18,231.25 +52.00 (+0.29%) Russell 2000 Futures
2,031.30 +11.50 (+0.57%) Crude Oil
85.38 -0.28 (-0.33%) Gold
2,371.50 -2.60 (-0.11%)
Bristol-Myers Squibb Company (BMY)
After hours:
Chart Events
Performance Outlook
| Previous Close | 49.12 |
| Open | 49.04 |
| Bid | 48.28 x 1000 |
| Ask | 48.50 x 1000 |
| Day's Range | 48.26 - 49.09 |
| 52 Week Range | 47.58 - 70.94 |
| Volume | |
| Avg. Volume | 16,064,195 |
| Market Cap | 97.852B |
| Beta (5Y Monthly) | 0.39 |
| PE Ratio (TTM) | 12.51 |
| EPS (TTM) | 3.86 |
| Earnings Date | Apr 25, 2024 |
| Forward Dividend & Yield | 2.40 (4.97%) |
| Ex-Dividend Date | Apr 04, 2024 |
| 1y Target Est | 52.52 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BMY
Related Research
- Bristol-Myers Squibb CompanyAnalyst Report: Bristol-Myers Squibb Co.Bristol-Myers Squibb is a leading worldwide biopharmaceutical company. Its products focus on oncology, immunology and cardiovascular conditions. The company completed its merger with Celgene in November 2019. BMY shares are a component of the S&P 500.RatingFair ValueEconomic Moat7 days agoArgus Research
ZacksThe Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals are part of the Zacks top Analyst Blog.
ZacksALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.
ACCESSWIREBuilding a Better Future: Bristol Myers Squibb 2023 ESG Report
NORTHAMPTON, MA / ACCESSWIRE / April 11, 2024 / Bristol Myers Squibb Company: At Bristol Myers Squibb, our vision is to transform patients' lives through science Originally published on Bristol Myers Squibb News & Perspectives Since 1887, BMS has ...
Simply Wall St.A Closer Look At Bristol-Myers Squibb Company's (NYSE:BMY) Impressive ROE
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
ZacksBiotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News
Moderna (MRNA) and Bristol Myers (BMY) are in focus on pipeline and regulatory updates.
BenzingaThe Pharmaceutical Industry Finds Itself At A Historical Crossroads
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE: JNJ) are facing the so-called patent cliffs which imply revenue of tens of billions of dollars between now and and the end of this decade is at risk. The expiration of patents for one or more leading branded products for a company means opening the door to competitors to sell copycats of those drugs, often at a competitive price. But, as always, pharmaceutical companies do their best
Motley Fool2 High-Yield Dividend Stocks Billionaires Are Buying Hand Over Fist
These reliable dividend payers offer yields of 3.3% and better at recent prices.
ZacksBristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.60, marking a +0.98% move from the previous day.
ZacksBristol Myers (BMY) Reports Positive Colorectal Cancer Study Data
Bristol Myers' (BMY) Krazati, in combination with cetuximab, demonstrates clinically meaningful activity as a targeted treatment option for patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer.
Motley Fool3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
Income-seeking investors can look forward to steady payout raises from these pharma stocks.
Morningstar Rating
Rating
Fair Value
Economic Moat
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| MRK Merck & Co., Inc. | |||
| LLY Eli Lilly and Company | |||
| ABT Abbott Laboratories | |||
| ABBV AbbVie Inc. | |||
| AMGN Amgen Inc. |
Similar to BMY
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| PFE Pfizer Inc. | |||
| GILD Gilead Sciences, Inc. | |||
| JNJ Johnson & Johnson | |||
| ABBV AbbVie Inc. | |||
| MRK Merck & Co., Inc. |
Analyst Price Targets (21)
Upgrades & Downgrades
| Maintains | Wells Fargo: Equal-Weight to Equal-Weight | 2/6/2024 | |
| Downgrade | Redburn Atlantic: Buy to Neutral | 2/6/2024 | |
| Downgrade | B of A Securities: Buy to Neutral | 1/3/2024 | |
| Maintains | B of A Securities: Buy to Buy | 12/27/2023 | |
| Downgrade | Cantor Fitzgerald: Overweight to Neutral | 11/15/2023 | |
| Initiated | Deutsche Bank: to Hold | 11/9/2023 |
Company Profile
Route 206 & Province Line Road
Princeton, NJ 08543
United States
609 252 4621
https://www.bms.com
Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full Time Employees: 34,100
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
